<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031083</url>
  </required_header>
  <id_info>
    <org_study_id>C-1502</org_study_id>
    <secondary_id>0101-453</secondary_id>
    <nct_id>NCT00031083</nct_id>
    <nct_alias>NCT00036725</nct_alias>
  </id_info>
  <brief_title>Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III &amp; Grade IV Gliomas</brief_title>
  <official_title>A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      In this study an investigational replication-defective, recombinant adenovirus expressing the&#xD;
      interferon-beta gene (BG00001) will be directly injected into tumors, in patients with&#xD;
      recurrent Grade III and Grade IV Gliomas, in order to deliver the hIFN-beta gene. The purpose&#xD;
      of the study is to evaluate the safety and any harmful effects of injection of BG00001 into&#xD;
      brain tumors. Also, this study will help determine whether the virus carrying the beta&#xD;
      interferon gene will enter brain tumor cells and cause the cancer cells to die. This study&#xD;
      will require one hospital admission for the actual procedure of drug administration. All&#xD;
      other visits will be conducted on an out-patient basis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2002</start_date>
  <completion_date type="Actual">October 10, 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Oligoastrocytoma, Mixed</condition>
  <condition>Gliosarcoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Interferon-beta</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be greater than or equal to 18 years of age.&#xD;
&#xD;
          2. Subjects must have histologically proven GBM, AA, AMO, malignant astrocytoma NOS or&#xD;
             gliosarcoma and recurrent or progressive tumor following prior treatment.&#xD;
&#xD;
          3. Tumor must be amenable to radical resection, and resection must be clinically&#xD;
             indicated.&#xD;
&#xD;
          4. Must have an ECOG performance status of 0-2.&#xD;
&#xD;
          5. Must be on anticonvulsant therapy, and must have therapeutic serum levels within 2&#xD;
             weeks prior to Day 1, if therapeutic levels are defined for the anticonvulsant being&#xD;
             used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Abnormal blood tests exceeding any of the limits defined below:&#xD;
&#xD;
               -  Alanine transaminase (ALT) &gt; four times (4X) the upper limit of normal (ULN).&#xD;
&#xD;
               -  Aspartate transaminase (AST) &gt; 4X the ULN.&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 mg/dL.&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1,500 cells/mm3.&#xD;
&#xD;
               -  Platelet count &lt;100,000 cells/mm3.&#xD;
&#xD;
               -  Serum creatinine &gt;2X ULN.&#xD;
&#xD;
               -  Prothrombin time (PT) &gt;2 seconds above the ULN.&#xD;
&#xD;
               -  Serum sodium (Na) &lt;125 mEq/L or &gt;150 mEq/L.&#xD;
&#xD;
               -  Serum potassium (K) &lt;3.5 mEq/L or &gt; 5.5 mEq/L.&#xD;
&#xD;
          2. Brainstem, or optic chiasm involvement of tumor.&#xD;
&#xD;
          3. Uncontrolled seizure disorder.&#xD;
&#xD;
          4. History of a new diagnosis or treatment of an invasive malignancy other than Grade III&#xD;
             or Grade IV Glioma within 5 years of enrollment. Curatively treated subjects with a&#xD;
             history of basal cell or squamous cell carcinoma of the skin, superficial transitional&#xD;
             cell carcinoma of the bladder, and non-invasive carcinoma of the uterine cervix are&#xD;
             not excluded.&#xD;
&#xD;
             Treatment History:&#xD;
&#xD;
          5. Treatment with radiation therapy, including interstitial radiation or radiosurgery,&#xD;
             must be completed at least 8 weeks prior to Day 1.&#xD;
&#xD;
          6. Treatment with nitrosoureas must be completed at least 6 weeks prior to Day 1.&#xD;
             Treatment with other chemotherapeutic agents must be completed at least 4 weeks prior&#xD;
             to Day 1.&#xD;
&#xD;
          7. Treatment with any investigational drug or approved therapy for investigational use&#xD;
             must be completed at least 4 weeks prior to Day 1.&#xD;
&#xD;
          8. History of intolerance to corticosteroids that would preclude use during this study,&#xD;
             or history of any medical condition that precludes the use of corticosteroids.&#xD;
&#xD;
          9. Any prior treatment with a gene delivery vector, or an adenovirus therapeutic.&#xD;
&#xD;
         10. Women of child bearing potential must have a negative serum pregnancy test.&#xD;
&#xD;
         11. Women who are not postmenopausal, surgically sterile, or willing to practice effective&#xD;
             contraception during the study. Men who are not surgically sterile or willing to&#xD;
             practice effective contraception during the study.&#xD;
&#xD;
         12. Nursing mothers, pregnant women and women planning to become pregnant while on study.&#xD;
&#xD;
         13. Previous treatment with BG00001.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona at Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 20, 2002</study_first_submitted>
  <study_first_submitted_qc>February 21, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2002</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Adenovirus</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Biogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

